N-Acetyl-L-aspartic acid
|
Basic information |
| Metabolite name | N-Acetyl-L-aspartic acid |
 | HMDB0000812 |
 |
C01042 |
 |
65065 |
| Synonyms | N-acetyl-aspartate; |
| No. of studies | 76 |
|
Basic information |
| Metabolite name | N-Acetyl-L-aspartic acid |
| HMDB0000812 |
|
C01042 |
|
65065 |
| Synonyms | N-acetyl-aspartate; |
| No. of studies | 76 |
|
Relationship between N-Acetyl-L-aspartic acid and depression (count: 76) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Up |
| Study M002 | Type1 | CUMS group vs. control group | Thalamus | Sprague-Dawley rat | Down |
| Study M002 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M002 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M025 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M047 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M047 | Type2 | CUMS + venlafaxine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M047 | Type2 | CUMS + high dose of genipin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M047 | Type2 | CUMS + low dose of genipin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M047 | Type2 | CUMS + middle dose of genipin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M048 | Type1 | CVS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M048 | Type2 | CVS + CSGS group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M053 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M054 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M068 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M068 | Type2 | CUMS + citalopram group vs. CUMS group | Urine | Sprague-Dawley rat | Up |
| Study M071 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Down |
| Study M071 | Type2 | CUMS + imipramine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Down |
| Study M074 | Type1 | sCSDS group vs. control group | Faece | C57BL/6JJmsSlc mouse | Up |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M076 | Type2 | CUMS + Anemarrhena saponins and Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M078 | Type1 | CORT model group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M078 | Type2 | CORT model + icariin group vs. CORT model group | Brain | Sprague-Dawley rat | Up |
| Study M082 | Type3 | medium dose of DG group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M082 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M083 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Up |
| Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Prefrontal cortex | Wistar rat | Up |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Plasma | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Hippocampus | Wistar rat | Up |
| Study M100 | Type1 | CS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M1024 | Type1 | CUMS group vs. control group | DG region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA1 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA3 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | DG region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA1 region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA3 region of hippocampus | ICR mouse | Up |
| Study M1058 | Type1 | depression group vs. control group | Basal ganglia | Human | Down |
| Study M1058 | Type1 | depression group vs. control group | Dorsal thalamus | Human | Down |
| Study M1058 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M1058 | Type1 | depression group vs. control group | Ventral prefrontal white matter | Human | Down |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell | Rat | Down |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M1072 | Type1 | CUMS group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M1080 | Type2 | non-refractory depression group, post 3-week treatment vs. baseline | Hippocampus | Human | Up |
| Study M1080 | Type4 | non-refractory depression group vs. refractory depression group, post 3-week treatment | Hippocampus | Human | Up |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Down |
| Study M110 | Type1 | SD group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M129 | Type3 | venlafaxine group vs. control group | Hippocampus | C57BL/6J mouse | Up |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M131 | Type1 | SD group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M131 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | LH group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M131 | Type1 | CRS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M135 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Unknown |
| Study M164 | Type1 | depressed group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M188 | Type1 | CFSS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M195 | Type1 | female early life stress group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M195 | Type1 | male early life stress group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M207 | Type1 | depressed group vs. control group | Hippocampus | Kunming mouse | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M209 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M221 | Type1 | stress group vs. control group | Brain | Tree shrew | Down |
| Study M246 | Type1 | stress group vs. control group | Brain | Tree shrew | Down |
| Study M262 | Type1 | stress group vs. control group | Brain | Tree shrew | Down |
| Study M278 | Type1 | depression group vs. control group | Anterior cingulate | Human | Down |
| Study M278 | Type1 | depression group vs. control group | Medial prefrontal cortex | Human | Down |
| Study M285 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M291 | Type1 | depression group vs. control group | Anterior cingulate | Human | Down |
| Study M291 | Type2 | ECT-treated depression group post-treatment vs. pre-treatment | Dorsolateral prefrontal cortex | Human | Down |
| Study M291 | Type2 | ECT-treated responder group post-treatment vs. pre-treatment | Anterior cingulate | Human | Up |
| Study M291 | Type2 | ECT-treated responder group post-treatment vs. pre-treatment | Dorsolateral prefrontal cortex | Human | Down |
| Study M305 | Type1 | chronic depression group vs. control group | Hippocampus | Human | Down |
| Study M310 | Type1 | depression group vs. control group | Anterior cingulate cortex | Human | Down |
| Study M311 | Type1 | OSAHS group vs. control group | Frontal white matter | Human | Down |
| Study M325 | Type1 | depression group vs. control group | Posterior cingulate cortex | Human | Down |
| Study M327 | Type1 | depression group vs. control group | Medial prefrontal cortex | Human | Down |
| Study M330 | Type1 | depression group vs. control group | Prefrontal cortex | Human | Down |
| Study M330 | Type2 | escitalopram + creatine group post-treatment vs. pre-treatment | Prefrontal cortex | Human | Up |
| Study M344 | Type1 | depression group vs. control group | Hippocampus | Human | Down |
| Study M344 | Type2 | ECT-treated depression group vs. control group | Hippocampus | Human | Down |
| Study M344 | Type2 | ECT-treated depression group vs. control group | Dorsal anterior cingulate cortex | Human | Down |
| Study M349 | Type1 | depression group vs. control group | Hippocampus | Human | Down |
| Study M355 | Type1 | stress group vs. control group | Brain | Tree shrew | Down |
| Study M355 | Type2 | stress + clomipramine group vs. stress group | Brain | Tree shrew | Up |
| Study M355 | Type2 | stress + L-760,735 group vs. stress group | Brain | Tree shrew | Up |
| Study M357 | Type1 | depression group vs. control group | Medial temporal cortex | Human | Down |
| Study M359 | Type2 | ECT-treated depression group post-treatment vs. pre-treatment | Anterior cingulate cortex | Human | Down |
| Study M463 | Type3 | DG group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M473 | Type1 | high-fat diet group vs. control group | Striatum | C57BL/6J mouse | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Hypothalamus | Wistar rat | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Hippocampus | Wistar rat | Down |
| Study M481 | Type1 | SD group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M491 | Type1 | post-CFSS vs. pre-CFSS | Prefrontal cortex | Wistar rat | Up |
| Study M511 | Type1 | Susceptible group vs. control group | Hippocampus | Wistar/ST rat | Up |
| Study M530 | Type1 | PDD group vs. control group | Brain | Human | Up |
| Study M530 | Type2 | PDD + duloxetine group vs. PDD group | Brain | Human | Down |
| Study M573 | Type1 | CSDS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M591 | Type1 | LPS group vs. control group | Prefrontal cortex | CD-1 mouse | Up |
| Study M591 | Type1 | LPS group vs. control group | Hippocampus | CD-1 mouse | Up |
| Study M595 | Type1 | CRS group vs. control group | Nucleus accumbens | C57BL/6J mouse | Down |
| Study M616 | Type1 | CUMS group vs. control group | Olfactory bulb | Sprague-Dawley rat | Down |
| Study M620 | Type1 | MDD group vs. control group | Parietal lobe | Human | Down |
| Study M620 | Type1 | MDD group vs. control group | Frontal lobe | Human | Down |
| Study M622 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M622 | Type2 | CUMS + JB-1 group, post- vs. pre-treatment | Hippocampus | Wistar rat | Up |
| Study M624 | Type1 | cognitive impairment with depression group vs. cognitive impairment group | Hippocampus | Human | Up |
| Study M633 | Type1 | corticosterone group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M633 | Type2 | corticosterone + Chrysanthemum morifolium group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M799 | Type1 | MDD group vs. control group | Middle temporal visual area | Human | Down |
| Study M823 | Type2 | CUMS + albiflorin group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M870 | Type2 | CRS + sertraline group vs. CRS group | Brain | C57BL/6 mouse | Up |
| Study M898 | Type1 | end-stage renal disease with depression group vs. end-stage renal disease without depression group | Serum | Human | Up |
| Study M911 | Type1 | CUS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M940 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Up |
| Study M940 | Type2 | CUMS + Chaihu group vs. CUMS group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M940 | Type2 | CUMS + Chaihu-Baishao herb pair group vs. CUMS group | Cerebral cortex | Sprague-Dawley rat | Down |